While the point estimate of the event rate ratio of documented symptomatic hypoglycaemia with BG ≤3.9 mmol/L over 30 weeks (second primary endpoint) favoured sitagliptin over placebo, the result was only marginally statistically significant.
← all excerpts
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
1
—
—